IDEXX LABORATORIES INC /DE (IDXX)

↓ Download CSV

CIK 0000874716 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, IDEXX LABORATORIES INC /DE reported revenue of $4.30B, up 10.4% from the prior year. The company was profitable, with a net margin of 24.6% and a gross margin of 61.8%. It held $3.35B in total assets against $1.75B in total liabilities.

Key ratios (FY2025)

61.8%
Gross margin
31.6%
Operating margin
24.6%
Net margin
66.0%
Return on equity
+10.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$4.30B$3.90B$3.66B$3.37B$3.22B$2.71B$2.41B$2.21B$1.97B$1.78B
Cost of Revenue$1.64B$1.52B$1.47B$1.36B
Gross Profit$2.66B$2.38B$2.19B$2.00B$1.89B$1.57B$1.37B$1.24B$1.10B$975.44M
Operating Income$1.36B$1.13B$1.10B$898.76M$932.03M$694.52M$552.85M$491.33M$413.03M$350.24M
Net Income$1.06B$887.87M$845.04M$679.09M$744.85M$581.78M$427.72M$377.03M$263.14M$222.04M
EPS (Diluted)$13.08$10.67$10.06$8.03$8.60$6.71$4.89$4.26$2.94$2.44
Total Assets$3.35B$3.29B$3.26B$2.75B$2.44B$2.29B$1.83B$1.54B$1.71B$1.53B
Total Liabilities$1.75B$1.70B$1.78B$2.14B$1.75B$1.66B$1.65B$1.55B$1.77B$1.64B
Shareholders' Equity$1.61B$1.60B$1.48B$608.74M$689.99M$632.09M$177.47M-$9.51M-$54.11M-$108.35M
Cash & Equivalents$180.07M$288.27M$453.93M$112.55M$144.45M$383.93M$90.33M$123.79M$187.68M$154.90M
Operating Cash Flow$1.18B$929.00M$906.51M$542.98M$755.55M$648.06M$459.16M$400.08M$373.28M
Capital Expenditures$124.68M$120.92M$133.63M$148.84M$119.55M$106.96M$154.97M$115.75M$74.38M$64.79M
Shares Outstanding81.03M83.25M83.98M84.60M86.57M86.72M87.54M88.47M89.57M90.88M